WHWK Whitehawk Therapeutics Inc.

Price (delayed)

$3.82

Market cap

$217.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$132.54M

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Aadi is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway, a key regulator of cell growth and ...

Highlights
The company's equity has surged by 57% QoQ and by 6% YoY
The company's EPS rose by 33% QoQ
WHWK's quick ratio has surged by 54% since the previous quarter but it is down by 15% year-on-year
Whitehawk Therapeutics's revenue has plunged by 100% YoY
The company's gross profit has shrunk by 100% YoY

Key stats

What are the main financial stats of WHWK

WHWK stock price

How has the Whitehawk Therapeutics stock price performed over time
Intraday
-5.45%
1 week
-5.45%
1 month
-19.24%
1 year
98.96%
YTD
57.85%
QTD
-16.59%

Financial performance

How have Whitehawk Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$86.06M
Net income
-$79.83M
Gross margin
N/A
Net margin
N/A
Whitehawk Therapeutics's revenue has plunged by 100% YoY
The company's gross profit has shrunk by 100% YoY
The company's net income rose by 31% QoQ
The operating income is up by 30% since the previous quarter and by 16% year-on-year

Price vs fundamentals

How does WHWK's price correlate with its fundamentals

Growth

What is Whitehawk Therapeutics's growth rate over time

Valuation

What is Whitehawk Therapeutics stock price valuation
P/E
N/A
P/B
1.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 33% QoQ
The company's equity has surged by 57% QoQ and by 6% YoY
WHWK's price to book (P/B) is 16% less than its 5-year quarterly average of 1.3 but 9% more than its last 4 quarters average of 1.0
Whitehawk Therapeutics's revenue has plunged by 100% YoY

Efficiency

How efficient is Whitehawk Therapeutics business performance
The return on invested capital has dropped by 69% year-on-year but it is up by 43% since the previous quarter
The return on assets has increased by 32% since the previous quarter
The company's return on equity rose by 32% QoQ

Dividends

What is WHWK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for WHWK.

Financial health

How did Whitehawk Therapeutics financials performed over time
WHWK's quick ratio has surged by 54% since the previous quarter but it is down by 15% year-on-year
WHWK's current ratio has soared by 53% QoQ but it is down by 15% YoY
The debt is 100% less than the equity
The company's equity has surged by 57% QoQ and by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.